TP53 and hepatocellular carcinoma: Similarly, three of the four cell lines (HepG2, HuH7, and HCC-4-4) appeared to display higher p21 expression after treatment with sorafenib versus vehicle control, while the fourth cell line (Hep3b) showed inconclusive results demonstrating approximately equal p21 expression levels despite markedly increased phospho-p53 expression in cells treated with sorafenib.